(S019) Genomic Homogeneity of Lung and Liver Metastases of a Unique Primary in Individual Patients

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

In this first-of-its-kind analysis, assessing the radiosensitivity of multiple metastases from the same patient, we note a similar radiosensitivity fingerprint for lesions from the liver and lung from the same primary lesion.

Kamran A. Ahmed, MD, Peter A. Johnstone, MD, Steven A. Eschrich, PhD, Javier F. Torres-Roca, MD; H. Lee Moffitt Cancer Center and Research Institute

BACKGROUND: The radiosensitivity index (RSI) is a multigene expression model of tumor radiosensitivity that has been validated in multiple clinical cohorts. We have previously reported significant differences in RSI between colon cancer metastases based on anatomical location. Here, we report findings of multiple metastases of a unique primary to the lung and liver.

METHODS: In an institutional review board-approved study, the Moffitt Cancer Center Total Cancer Care biorepository was screened for metastatic lung and liver lesions from the same patient. Gene expression was assessed using Affymetrix Hu-RSTA-2a520709. The previously tested RSI 10-gene assay was run on tissue samples.

RESULTS: The median RSI for all liver lesions was 0.42 (quartile 1 [Q1], 0.31; quartile 3 [Q3], 0.49) vs 0.36 for lung lesions (Q1, 0.30; Q3, 0.47; P = .26); this is congruent with our prior published data. A total of 57 patients had multiple metastatic liver tissue samples (n = 123) available for analysis. Primary lesions included colorectal (89%, n = 110), breast (5%, n = 6), lung (3%, n = 4), and anal (2%, n = 3) tumors. The deviation from the mean for metastatic tumor samples from the same patient was 0.017 (Q1, 0.003; Q3, 0.035). A total of 30 patients had multiple metastatic lung tissue samples (n = 62). Primary lesions included colorectal (58%, n= 36), soft tissue (16%, n = 10), kidney (13%, n = 8), breast (6%, n = 4), and skin (6%, n = 4). The deviation from the mean for metastatic lung samples from the same patient was 0.023 (Q1, 0.0019; Q3, 0.059).

CONCLUSIONS: In this first-of-its-kind analysis, assessing the radiosensitivity of multiple metastases from the same patient, we note a similar radiosensitivity fingerprint for lesions from the liver and lung from the same primary lesion. This may be due to milieu-based selection of a unique metastatic clone or by re-metastasis of an existing metastatic lesion and warrants further experimental validation. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content